NEW YORK (AP) - ImClone Systems Inc., the maker of colon cancer treatment Erbitux, said Tuesday that first-quarter earnings fell sharply from a year ago due to lower revenue, higher compensation expenses associated with increased head count and higher professional fees, primarily for...More
Wednesday, April 27, 2005
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment